recro_logo.jpg
Recro Pharma Presents Clinical Data at PAINWeek 2016
September 07, 2016 16:05 ET | Recro Pharma, Inc.
MALVERN, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...
recro_logo.jpg
Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 06, 2016 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care...
recro_logo.jpg
Recro Pharma Announces Closing of Public Offering of Common Stock
August 19, 2016 10:38 ET | Recro Pharma, Inc.
MALVERN, Pa., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...
recro_logo.jpg
Recro Pharma Announces Pricing of Public Offering of Common Stock
August 16, 2016 09:00 ET | Recro Pharma, Inc.
MALVERN, Pa., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...
recro_logo.jpg
Recro Pharma Announces Proposed Public Offering of Common Stock
August 15, 2016 18:05 ET | Recro Pharma, Inc.
MALVERN, Pa., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...
recro_logo.jpg
Recro Pharma Reports Second Quarter 2016 Financial Results
August 11, 2016 07:00 ET | Recro Pharma, Inc.
Announced Positive Top-line Results from Pivotal Phase III Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam in Abdominoplasty Ongoing with Top-line...
recro_logo.jpg
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
July 26, 2016 16:05 ET | Recro Pharma, Inc.
IV Meloxicam Achieves Primary Endpoint in First of Two Pivotal Trials Fifteen of Nineteen Secondary Endpoints Also Met Management to Host Conference Call and Webcast Today at 5:00 PM ET ...
recro_logo.jpg
Recro Pharma Appoints Michael Celano as Chief Financial Officer
July 05, 2016 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., July 05, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
recro_logo.jpg
Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
June 02, 2016 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., June 02, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care...
recro_logo.jpg
Recro Pharma Reports First Quarter 2016 Financial Results
May 12, 2016 09:07 ET | Recro Pharma, Inc.
Enrollment on track in two pivotal Phase III IV meloxicam trials One trial expected to report top-line results by end of Q3; Other trial to report top-line results by end of Q4 Manufacturing...